Palbociclib Associated Deep Vein Thrombosis: A Case Report
PDF

Case report

Palbociclib Associated Deep Vein Thrombosis: A Case Report

Acta Haematol Oncol Turc 2022;55(1):68-71 DOI: 10.5505/aot.2022.59751
,
PDF
Permissions

Abstract

Cyclin-D-cyclin dependent kinase 4/6 (CDK 4/6) inhibitors started a new era in metastatic hormone receptor positive breast cancer. Ribociclib, palbociclib and abemaciclib (CDK 4/6 inhibitors) are used in combination with endocrine therapy and they provided a significant benefit in progression free and overall survival. Fatigue, neutropenia, anemia, and diarrhea are commonly seen side effects which are easily manageable with dose modifications. Herein, we presented a case of deep vein thrombosis developed twice under palbociclib treatment which is a rarely reported side effect causing cessation of the treatment.

Keywords: CDK4/6 inhibitors, metastasis, thrombosis